Evidence map›Paper›PMID 40131546›Full record

ArticleBiodegradation2025

Enhanced bio-reduction of Cr(VI) using Shewanella putrefaciens CN32 mediated by Fe(III) minerals and riboflavin synergistically.

Tianle Zhang, Haibo Li, Yichen Wu, Yajue Yuan, Yu Du

Abstract read
PubMed Publisher
In one paragraph

Article in Biodegradation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tianle ZhangSchool of Resources and Civil Engineering, Northeastern University, Shenyang, 110819, China.
Haibo LiSchool of Resources and Civil Engineering, Northeastern University, Shenyang, 110819, China. lihaibo@mail.neu.edu.cn.
Yichen WuSchool of Resources and Civil Engineering, Northeastern University, Shenyang, 110819, China.
Yajue YuanSchool of Resources and Civil Engineering, Northeastern University, Shenyang, 110819, China.
Yu DuSchool of Resources and Civil Engineering, Northeastern University, Shenyang, 110819, China.

Funding

Key Technologies Research and Development Program 2024YFC2909605
6 · The paper itself

Abstract

Iron minerals and the coupling of electron shuttle media can effectively overcome the problem of the insolubility of iron minerals and the higher cross-medium resistance consequently to enhance the bio-reduction rate of Cr(VI) by dissimilatory metal-reducing bacteria (DMRB). This study explored the potential synergistic enhancement of Cr(VI) bio-reduction by Shewanella putrefaciens CN32 in combination with three iron minerals (ferrihydrite, goethite and hematite) and riboflavin (RF). The addition of RF accelerates the transfer of electrons from bacterial cells to Fe minerals, which in turn promotes the production of large amounts of Fe(II). The results indicated that compared to the control group, the Cr(VI) reduction rates in the CN32/RF/hematite, goethite, ferrihydrite systems increased to 93.03%, 91.07%, and 86.83%, hematite was capable of generating 2.24 mM Fe(II) due to its stable structure and efficient synergy with riboflavin. Enhancement factor(EF) was used to quantify the synergistic effect of RF and iron minerals on the bio-reduction of Cr(VI). At all three reaction times, the F

Indexed as

ChromiumFerric CompoundsMineralsRiboflavinShewanella putrefaciensBiodegradation, EnvironmentalIron CompoundsOxidation-ReductionChromiumchromium hexavalent ionFerric Compoundsferric oxideferric oxyhydroxidegoethiteIron CompoundsMineralsRiboflavinCr(VI) bio-reductionExtracellular electron transferFe mineralsRibofavinShewanella putrefaciens CN32

Identifiers

PMID40131546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.